The KIF5A Knockout HeLa Polyclonal Cells product provides a CRISPR/Cas9-mediated disruption of the KIF5A gene in the widely used HeLa cell line, generating a heterogeneous polyclonal knockout population. This model enables loss-of-function studies of kinesin family member 5A, the heavy chain motor subunit of kinesin-1, a critical motor protein for anterograde microtubule-dependent transport. The polyclonal format reflects a pool of cells harboring diverse gene edits, offering a robust and experimentally tractable system for investigating intracellular trafficking without the need for clonal isolation. Researchers can utilize these cells to dissect the functional consequences of KIF5A ablation in a human cervical adenocarcinoma background.
HeLa cells, derived from an aggressive cervical adenocarcinoma, represent an immortalized epithelial line that has been instrumental in biomedical research for decades. Their robust proliferation, ease of genetic manipulation, and compatibility with advanced imaging and biochemical assays make them an ideal host for studying motor protein dynamics in cancer cell biology. The HeLa background endogenously expresses key kinesin-1 components and cargo adaptors, providing a relevant context to examine how loss of KIF5A perturbs organelle transport and cellular homeostasis within a malignant epithelial setting.
KIF5A encodes a kinesin-1 heavy chain that, together with kinesin light chains (KLC1), facilitates the processive transport of diverse cargoes along microtubules. It is responsible for the anterograde movement of mitochondria, synaptic vesicles, Trk receptors, RNA granules, and lysosomes. The motor activity is regulated by upstream factors including ATP, CaMKII, and JNK, while adaptor proteins such as TRAK1, TRAK2, syntabulin, and GRIF-1 mediate specific cargo coupling. KIF5A interacts with microtubule-associated proteins MAP1B and Tau, and its function is integrated within the broader kinesin-1 family (KIF5A/B/C) and balanced by retrograde dynein-dependent transport. Disruption of KIF5A therefore impairs the coordinated trafficking essential for mitochondrial distribution and neurotrophic signaling.
In the context of HeLa cells, the KIF5A knockout population offers a unique platform to delineate the role of kinesin-1-mediated transport in cancer cell physiology. Mitochondrial trafficking is particularly relevant in highly proliferative cancer cells, influencing energy metabolism, reactive oxygen species production, and apoptotic signaling. The polyclonal nature of the knockout allows observation of phenotypic variability and facilitates experiments that require bulk population analyses, such as drug response profiling or biochemical fractionation. By studying KIF5A loss in a cervical cancer model, researchers can investigate potential links between intracellular transport defects and malignant transformation, therapeutic resistance, or metastasis.
These polyclonal knockout cells are well-suited for a range of experimental applications, including live-cell imaging of mitochondrial dynamics, co-immunoprecipitation of kinesin complexes, Western blotting, RT-qPCR, and immunofluorescence microscopy. They enable motor protein characterization, drug screening for trafficking defects, and modeling of neurodegenerative disorders like hereditary spastic paraplegia (SPG10) and Charcot-Marie-Tooth disease type 2 in a tractable cell system. The model also supports studies of axonal transport mechanisms relevant to amyotrophic lateral sclerosis. For additional information or customization options, please contact Ascent Research.
